Liu Gang, Xiong Disheng, Zeng Junjie, Chen Borong, Huang Zhengjie
Department of Gastrointestinal Surgery, Xiamen Cancer Hospital of the First Affiliated Hospital of Xiamen University, Xiamen.
Department of Gastrointestinal Surgery, The First Clinical Medical College of Fujian Medical University, Fuzhou, People's Republic of China.
Onco Targets Ther. 2017 Sep 1;10:4321-4328. doi: 10.2147/OTT.S143089. eCollection 2017.
The prognostic significance of Ki-67 in patients with gastric cancer (GC) remains controversial. The aim of our meta-analysis is to evaluate its association with clinicopathological characteristics and prognostic value in patients with GC. PubMed, EMBASE, and Web of Science were systematically searched up to May 2017. Twenty-two studies including 3,825 patients with GC were analyzed. The meta-analysis indicated that the incidence difference of Ki-67 expression in GC patients was significant when comparing the older group to younger group (odds ratio [OR] =1.44, 95% confidence interval [CI] 1.19, 1.75), lymph node positive group to negative group (OR =1.49, 95% CI 1.20, 1.84), the large size tumor group to the small size tumor group (OR =1.27, 95% CI 1.24, 1.68) and the TNM stage III+IV group to TNM stage I+II group (OR =2.28, 95% CI 1.66, 3.12). However, no statistical differences existed in gender. The detection of Ki-67 significantly correlated with the overall survival of patients (hazard ratio =1.51, 95% CI 1.31, 1.72). Our study suggested that Ki-67 overexpression was associated with poor prognosis in GC patients. Ki-67 positive rates may be associated with age, lymph node metastasis, tumor size, and TNM staging system in GC patients.
Ki-67在胃癌（GC）患者中的预后意义仍存在争议。我们进行这项荟萃分析的目的是评估其与GC患者临床病理特征的关联以及预后价值。截至2017年5月，我们系统检索了PubMed、EMBASE和Web of Science。分析了22项研究，共纳入3825例GC患者。荟萃分析表明，在GC患者中，比较老年组与年轻组时，Ki-67表达的发生率差异具有统计学意义（比值比[OR]=1.44，95%置信区间[CI]为1.19，1.75）；比较淋巴结阳性组与阴性组时（OR =1.49，95% CI 1.20，1.84）；比较大尺寸肿瘤组与小尺寸肿瘤组时（OR =1.27，95% CI 1.24，1.68）；以及比较TNM III + IV期组与TNM I + II期组时（OR =2.28，95% CI 1.66，3.12）。然而，性别方面不存在统计学差异。Ki-67的检测与患者的总生存期显著相关（风险比=1.51，95% CI 1.31，1.72）。我们的研究表明，Ki-67过表达与GC患者的预后不良相关。GC患者的Ki-67阳性率可能与年龄、淋巴结转移、肿瘤大小和TNM分期系统有关。
